TABLE 4.

Nanoformulation of sorafenib with PLGA, chitosan, and poloxamer (0.5, 1, 1.5, and 2%).

No.	Drug: PLGA (mg)	Chitosan (% w/v)	Poloxamer 407 (%)	Size (nm)	PDI	ZP (mv)	(%) EE	(%) DL
Polox38	1:5	0.2	0.5	151 ± 11.12	0.279 ± 0.02	5.7 ± 0.01	47	7.4
Polox39	2:5	0.2	0.5	159 ± 10.27	0.129 ± 0.03	5.77 ± 1.2	56	7.7
Polox40	3:5	0.2	0.5	160 ± 8.65	0.163 ± 0.03	6.7 ± 0.34	53	13.7
Polox41	4:5	0.2	0.5	161 ± 14.38	0.119 ± 0.02	6.72 ± 1.4	62	19.1
Polox42	1:5	0.2	1.0	166 ± 21.32	0.148 ± 0.04	7.02 ± 1.8	67	14.6
Polox43	2:5	0.2	1.0	169 ± 7.64	0.193 ± 0.02	16 ± 0.04	69	9.7
Polox44	3:5	0.2	1.0	173 ± 17.66	0.165 ± 0.01	16 ± 1.52	71	10.8
Polox45	4:5	0.2	1.0	177 ± 25.15	0.187 ± 0.03	17 ± 0.22	75	11.2
Polox46	1:5	0.2	1.5	181 ± 11.36	0.192 ± 0.03	19 ± 0.7	81	8.1
Polox47	2:5	0.2	1.5	187 ± 12.74	0.147 ± 0.01	20 ± 1.5	79	7.6
Polox48	3:5	0.2	1.5	189 ± 24.22	0.155 ± 0.02	23 ± 0.56	74	7.9
Polox49	4:5	0.2	1.5	199 ± 18.41	0.202 ± 0.04	30.7 ± 0.08	76	8.2
Polox50	1:5	0.2	2.0	200 ± 13.13	0.233 ± 0.01	32 ± 0.11	87	8.8
Polox51	2:5	0.2	2.0	237 ± 16.61	0.160 ± 0.03	48 ± 0.13	75	9.0
Polox52	3:5	0.2	2.0	244 ± 23.63	0.149 ± 0.04	49 ± 0.11	69	13.4
Polox53	4:5	0.2	2.0	262 ± 14.49	0.079 ± 0.04	66 ± 0.24	64	11.1